注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
醣基生醫股份有限公司主要從事於醣分子相關技術之新藥開發。該公司擁有之平台技術與產品開發依其專利特性可分為八大類,包括:均相化抗體藥物、癌症與免疫相關疾病之單株抗體藥物、醣類相關疫苗與藥物、抗流感藥物、醣精片開發與應用、醣探針開發與應用、醣分子合成鑒定及應用開發、創新開發計劃衍生專利。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Chinh-Yi Wu | - | 2022 | GM & Board Member |
Ming-Hsing Tsai | 66 | 2022 | Director |
Chao-Long Chen | - | - | Chairman |
Shaw T. Chen | - | - | Member of Scientific Advisory Board |
Chi-Huey Wong | - | - | Chairman of Scientific Advisory Board |
Hsieng S. Lu | - | - | Member of Scientific Advisory Board |
Shuan-Ta Liu | - | 2019 | Independent Director |
Kuo-I Lin | - | 2021 | Member of Scientific Advisory Board |
Che Alex Ma | - | - | Member of Scientific Advisory Board |
Pan-Chyr Yang | - | - | Member of Scientific Advisory Board |
Chung-Yi Wu | - | 2022 | President, CEO, GM & Director |
Yun-Ching Yeh | - | 2022 | Board Member |
Victor Ma | - | 2022 | Board Member |
Mei-Shang Ho | - | 2021 | Member of Scientific Advisory Board |
Hong-Nerng Ho | - | - | Independent Director |
Chung-Liang Chien | - | - | Independent Director |
Shun-Ling Chen | - | 2022 | Board Member |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核